Health knowledge made personal
Join this community!
› Share page:
Search posts:

Development of a New Carbohydrate Antibody to GalNac1-3Gal

Posted Aug 10 2009 5:00pm

Description of Invention:
The present invention provides a monoclonal antibody that binds specifically to the antigen GalNAc1-3Gal present in human cancers, including squamous cell cancer, human cervical cancer, human esophageal cancer, human laryngeal cancer, and, human skin cancer. The antibody can be used to monitor expression of this carbohydrate for a variety of purposes. In immunohistochemical staining of tissues, the antibody stains a variety of carcinomas, with good staining of cervical, larynx, and skin squamous cell carcinomas. Positive antibody staining of cervical cancer tissue correlates with a good prognosis (increased 5 year survival rate) as such may be useful as a prognostic marker. NCI also has the parent cell line for production of the antibody and several other variant antibodies with similar reactivity.

  • Cervical cancer diagnostics and prognosis
  • Research tool

Jeff C Gildersleeve (NCI)

Patent Status:
HHS, Reference No. E-058-2009/0
US, Application No. 61/165,675 filed 01 Apr 2009
US, Application No. 12/752,331 filed 01 Apr 2010

Licensing Status:
Available for licensing.

Cancer - Diagnostics
Cancer - Research Materials

For Additional Information Please Contact:
Betty Tong Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-594-6565
Fax: 301-402-0220

Ref No: 1997

Updated: 08/2009

Post a comment
Write a comment:

Related Searches